Development of a cobalt(<scp>iii</scp>)-based ponatinib prodrug system
Marlene Mathuber, Michael Gutmann, Mery La Franca, Petra Vician, Anna Laemmerer, Patrick Moser, Bernhard K. Keppler, Walter Berger, Christian R. Kowol
Abstract
This study presents the first hypoxia-activatable cobalt(<sc>iii</sc>) prodrugs of the clinically approved tyrosine kinase inhibitor ponatinib. The chemical properties of the complexes have been correlated with the<italic>in vivo</italic>antitumor activity.
Topics & Concepts
ProdrugPonatinibCobaltChemistryPharmacologyBiochemistryMedicineDasatinibOrganic chemistryReceptorTyrosine kinasePlant Disease Resistance and GeneticsFungal Plant Pathogen ControlSynthesis and Biological Evaluation